Skip to Content
R. Frank  Cornell

R. Frank Cornell, M.D.

Assistant Professor of Medicine (Hematology/Oncology)

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    (615) 322-4967

    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Nashville Veterans Affairs Medical Center
    (615) 327-4751 or (800) 228-4973

  • Faxes
    Division of Hematology/Oncology Fax
    (615) 343-7602
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Nashville Veterans Affairs Medical Center Fax
    (615) 873-7901
  • Addresses
    Vanderbilt University Medical Center
    Division of Hematology/Oncology
    1301 Medical Center Drive, 3927 TVC
    Nashville, TN 37232-5505

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307

    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415

    Nashville Veterans Affairs Medical Center
    1310 24th Ave. South
    Nashville , TN 37212-2637


Dr. Cornell is an assistant professor of medicine. He received a B.S. in clinical laboratory science from Saint Louis University and then worked in clinical and molecular hematology at Johns Hopkins Hospital. He attended medical school at Trinity College in Dublin, Ireland. Dr. Cornell then completed his Internal Medicine Residency and Hematology/Oncology Fellowship at The Medical College of Wisconsin. He obtained his Master's in Clinical and Translational Science.

He specializes in the treatment of plasma cell disorders including Multiple Myeloma, Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, Amyloid Light-Chain (AL) Amyloidosis, Plasma Cell Leukemia, Solitary Plasmacytoma and Waldenstrom Macroglobulinemia.

Dr. Cornell's research focuses on translational and early phase clinical trials for the treatment of multiple myeloma. He also conducts research and clinical trials for relapsed/refractory multiple myeloma and other plasma cell disorders. He also researches cardio-oncology to better understand the effects of chemotherapy on the heart and vascular system.

Dr. Cornell is an active member of the American Society of Hematology, American Society of Clinical Oncology, International Society of Cardio-Oncology, and the American Society for Blood and Marrow Transplantation. He is a member of the multiple myeloma subcommittee of ASBMT.

  • Saint Louis University, B.S. (Clinical Laboratory Science), 2000
  • Trinity College Dublin Medical School, M.D., 2007
  • Internship/Residency - Internal Medicine, Medical College of Wisconsin, 2010
  • Fellowship - Hematology/Oncology, Medical College of Wisconsin, 2013
  • Master of Clinical and Translational Science, Medical College of Wisconsin, 2014
  • Cornell RF, Hari P, Drobyski WR. Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. Biol. Blood Marrow Transplant [print-electronic]. 2015 Dec; 21(12): 2061-8. PMID: 26327628, PMCID: PMC4639405, PII: S1083-8791(15)00578-9, DOI: 10.1016/j.bbmt.2015.08.030, ISSN: 1523-6536.
    Available from:
  • Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant [print-electronic]. 2015 Dec; 50(12): 1513-8. PMID: 26301967, PMCID: PMC4548821, PII: bmt2015190, DOI: 10.1038/bmt.2015.190, ISSN: 1476-5365.
    Available from:
  • D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J. Clin. Oncol [print-electronic]. 2015 Nov 11/10/2015; 33(32): 3741-9. PMID: 26371138, PII: JCO.2015.62.4015, DOI: 10.1200/JCO.2015.62.4015, ISSN: 1527-7755.
    Available from:
  • Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant [print-electronic]. 2015 Jul 7/20/2015; PMID: 26191950, PII: bmt2015164, DOI: 10.1038/bmt.2015.164, ISSN: 1476-5365.
    Available from:
  • Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant [print-electronic]. 2015 Jul; 50(7): 914-7. PMID: 25915809, PII: bmt201573, DOI: 10.1038/bmt.2015.73, ISSN: 1476-5365.
    Available from:
  • Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail [print-electronic]. 2015 Feb; 21(2): 138-44. PMID: 25433360, PII: S1071-9164(14)01307-4, DOI: 10.1016/j.cardfail.2014.11.008, ISSN: 1532-8414.
    Available from:
  • Cornell RF, Burns LJ, Bachanova V. Why Waldenstrom macroglobulinemia is not just another indolent lymphoma. 2014.
  • Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant [print-electronic]. 2013 Sep; 19(9): 1368-73. PMID: 23806770, PII: S1083-8791(13)00288-7, DOI: 10.1016/j.bbmt.2013.06.017, ISSN: 1523-6536.
    Available from:
  • Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW. Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. Case Rep Endocrinol [print-electronic]. 2013; 2013: 675298. PMID: 24455332, PMCID: PMC3881387, DOI: 10.1155/2013/675298, ISSN: 2090-6501.
    Available from:
  • Cornell RF, Palmer J, Komorowski R, Drobyski WR. Surgical resection as definitive treatment for refractory GVHD of the colon. Bone Marrow Transplant [print-electronic]. 2012 Oct; 47(10): 1366-7. PMID: 22327134, PII: bmt201215, DOI: 10.1038/bmt.2012.15, ISSN: 1476-5365.
    Available from:
  • Cornell RF, Palmer J. Adult acute leukemia. Dis Mon. 2012 Apr; 58(4): 219-38. PMID: 22449370, PII: S0011-5029(12)00012-0, DOI: 10.1016/j.disamonth.2012.01.011, ISSN: 1557-8194.
    Available from:
  • Cornell RF, Fenske TS.. Indolent B-Cell Non-Hodgkin Lymphoma. 2011.
  • Cornell RF, Randolph TR. The minimum concentration of fibrinogen needed for platelet aggregation using ADP. Clin Lab Sci. 2002; 15(1): 30-6. PMID: 12778954, ISSN: 0894-959X.
    Available from: